Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,648 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,490)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05144997 | Lorlatinib Continuation Study | active not recruiting | Phase 4 | 76 | PfizerINDUSTRY | 8 | Sep 23, 2026 | clinicaltrials |
| NCT06282874 | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases | active not recruiting | Phase 4 | 41 | Guangdong Association of Clinical TrialsOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05160922 |
| Crizotinib Continuation Clinical Study |
| active not recruiting |
| Phase 4 |
| 27 |
| PfizerINDUSTRY |
| 5 |
| Mar 30, 2026 |
| clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials